Insmed Incorporated (INSM)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 164 | 188 | 245 | 305 | 364 | 606 | 1,138 | 1,804 |
| Operating profit | $m | -1,177 | -818 | ||||||
| Net profit | $m | -294 | -435 | -482 | -750 | -914 | -1,277 | -875 | -345 |
| EPS reported | $ | -6.41 | -4.11 | ||||||
| Operating cashflow per share | $ | -4.38 | -3.58 | ||||||
| Capex per share | $ | 0.15 | 0.27 | ||||||
| FCF per share | $ | -4.53 | -3.85 | ||||||
| Free cash flow | $m | -968 | -838 | ||||||
| Net debt | $m | -695 | -617 | ||||||
| Book value equity | $m | 739 | 757 | ||||||
| Book value per share | $ | 3.46 | 3.49 | ||||||
| Number of shares | m | 213.64 | 217.35 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 50.31 | 49.08 | ||||||
| P/S LTM | x | 61.31 | 32.68 | ||||||
| P/FCF LTM | x | -38.43 | -44.39 | ||||||
| EV/EBITDA LTM | x | -31.96 | -48.62 | ||||||
| EV/Sales LTM | x | 61.74 | 23.61 | ||||||
| Earnings Yield LTM | % | -3.43% | -3.25% | ||||||
| FCF Yield | % | -2.60% | -2.25% | ||||||
| Quality | |||||||||
| ROE | % | -172.78% | -111.26% | ||||||
| ROIC | % | -64.84% | -48.85% | ||||||
| Operating margin | % | -1.94% | -71.86% | ||||||
| Gross margin | % | +79.41% | +83.27% | ||||||
| FCF/Sales | % | -159.55% | -73.63% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +66.73% | +212.79% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.26 | -1.44 | ||||||
| Net Debt/EBITDA | x | -0.22 | -0.05 | ||||||
| EBIT/Net interest | x | -14.04 | -10.05 | ||||||
| Net debt/market cap | % | +1.98% | +2.03% | ||||||
| Net debt/Equity | x | -0.94 | -0.81 | ||||||
| Gross debt/equity | x | 1.04 | 0.77 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free